istock-936761078-marrio31

marrio31 / iStockphoto.com

20 November 2018Americas

LSPN Europe 2018: Russian litigation and US second medical use

The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More on this story

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

19 November 2018 The UK has an excellent opportunity to adopt laws on supplementary protection certificates that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers

16 November 2018 Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More features

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?